GLP-1RA- and Incretin-Based Therapies Within Lifestyle Interventions for Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis
Nutrients · 2026
DOI: 10.3390/nu18111781 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Nutrients, 2026. Verfasst von Alejandro Bruna-Mejias und 7 weiteren Autor:innen. Beteiligte Einrichtung: Programa de Doctorado en Investigación Aplicada a las Ciencias Sanitarias, Escuela de Doctorado, Universidad de Las Palmas de Gran Canaria (ULPGC), 3…. Hauptthemen laut MEDLINE: Incretins, Obesity, Overweight, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Glucagon-like peptide-1 receptor agonist (GLP-1RA)- and incretin-based therapies are now central to obesity management. Their clinical value, however, should be interpreted beyond total weight loss, because changes in fat mass, lean mass, physical function, and cardiometabolic risk may depend on the accompanying dietary, behavioral, and exercise co-interventions. This systematic review and meta-analysis evaluated GLP-1RA- and incretin-based therapies delivered within lifestyle interventions in adults with overweight or obesity.
Methods
The protocol was registered in PROSPERO (CRD420261360837). PubMed/MEDLINE, Web of Science, Scopus, CINAHL, SPORTDiscus, and CENTRAL were searched from inception to the final search dates. Records were deduplicated in Zotero. Risk of bias was assessed using the Cochrane RoB 2 tool. Random-effects meta-analyses were estimated using restricted maximum likelihood with Hartung–Knapp adjustment when pooling was appropriate.
Results
Across all database sources, 1651 records were identified. After removing 113 duplicate records and 212 records with an ineligible publication type before screening, 1326 records were screened. Seventy-seven reports were sought for retrieval, five were not retrieved, 72 were assessed at full text, and 48 reports corresponding to 35 independent parent trials or trial clusters were retained for qualitative synthesis. The primary kilogram-scale meta-analysis included eight independent comparisons and showed greater body-weight reduction with GLP-1RA/incretin-based therapy delivered within a lifestyle background than with placebo/control (mean difference [MD] −10.08 kg, 95% confidence interval [CI] −12.76 to −7.39; 95% prediction interval [PI] −17.86 to −2.29; I2 = 95.6%). Percentage body-weight change was analyzed separately across 11 independent comparisons and also favored GLP-1RA/incretin-based therapy (MD −9.53 percentage points, 95% CI −11.92 to −7.14; 95% PI −17.58 to −1.48; I2 = 95.4%).
Conclusions
GLP-1RA- and incretin-based therapies delivered within lifestyle interventions are associated with clinically meaningful reductions in body weight in adults with overweight or obesity. Absolute and relative body-weight change metrics should remain analytically separate. The magnitude of benefit varies across trial contexts, and certainty remains limited by risk-of-bias concerns and considerable heterogeneity. Future trials should standardize the reporting of lifestyle co-interventions, body composition, adherence, physical-function outcomes, and safety monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Programa de Doctorado en Investigación Aplicada a las Ciencias Sanitarias, Escuela de Doctorado, Universidad de Las Palmas de Gran Canaria (ULPGC), 35001 Las Palmas de Gran Canaria, Spain.
- Escuela de Medicina, Facultad de Medicina, Universidad Andrés Bello, Viña del Mar 2520000, Chile.
- Department of Chemical and Biological Sciences, Faculty of Health Sciences, Universidad Bernardo O'Higgins, Santiago 8370993, Chile.
- Faculty of Health Sciences, Universidad Autónoma de Chile, Santiago 8910060, Chile.
- Faculty of Health and Social Sciences, Universidad de Las Américas, Santiago 8370040, Chile.
- School of Kinesiology, Faculty of Medicine, Universidad Mayor, Santiago 7500000, Chile.
ORCID-Profile: Alejandro Bruna-Mejias, Mathias Orellana-Donoso, Gloria Cifuentes-Suazo, Juan Francisco Loro-Ferrer
Zitieren
APA
Bruna-Mejias, A., Valenzuela-Fuenzalida, J. J., Oyanedel, G., Figueroa-Puig, J., Cabezas-Salgado, J. J., Orellana-Donoso, M., Cifuentes-Suazo, G., & Loro-Ferrer, J. F. (2026). GLP-1RA- and Incretin-Based Therapies Within Lifestyle Interventions for Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis. Nutrients. https://doi.org/10.3390/nu18111781
Vancouver
Bruna-Mejias A, Valenzuela-Fuenzalida JJ, Oyanedel G, Figueroa-Puig J, Cabezas-Salgado JJ, Orellana-Donoso M, et al. GLP-1RA- and Incretin-Based Therapies Within Lifestyle Interventions for Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis. Nutrients. 2026. doi:10.3390/nu18111781
BibTeX
@article{BrunaMejias2026,
author = {Bruna-Mejias, Alejandro and Valenzuela-Fuenzalida, Juan José and Oyanedel, Gustavo and Figueroa-Puig, Julio and Cabezas-Salgado, Juan José and Orellana-Donoso, Mathias and Cifuentes-Suazo, Gloria and Loro-Ferrer, Juan Francisco},
title = {GLP-1RA- and Incretin-Based Therapies Within Lifestyle Interventions for Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis},
journal = {Nutrients},
year = {2026},
doi = {10.3390/nu18111781}
}
EUVIMED